Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;45(11):681-692.
doi: 10.1159/000526481. Epub 2022 Aug 19.

Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer

Jiaxuan Liu  1 , Maiyue He  1 , Zijing Wang  1 , Qiao Li  1 , Binghe Xu  1
Affiliations
Review

Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer

Jiaxuan Liu et al. Oncol Res Treat. 2022.

Abstract

Background: Metronomic chemotherapy (MCT), termed sustained low-dose administration with minimal toxicity, is a new modality of conventional chemotherapy, a verified therapy alternative, and has acquired significant recognition and interest in oncology. Numerous clinical trials of MCT in combination with other treatments, including targeted therapies, biologics, and endocrine therapy, are in progress to obtain better results.

Summary: We comprehensively described the clinical benefits of MCT in combination with other treatments in different molecular subtypes of breast cancer and assessed the feasibility of its adoption in varying phases of treatment. Due to the promising preclinical and clinical investigations, it is expected that MCT in combination with other treatments will enhance the advantages of this strategy and apply it to clinical practice.

Key message: MCT, in combination with other therapeutic interventions, will fully exploit the benefits of this strategy, ushering in a new paradigm in oncology treatment and driving the transformation of cancer into a more manageable chronic disease using newly developed treatment approaches.

Keywords: Breast cancer; Combination treatment; Metronomic chemotherapy; Molecular subtype.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. DeVita VT, Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68((21)):8643–8653. - PubMed
    1. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60((7)):1878–1886. - PubMed
    1. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105((8)):R15–R24. - PMC - PubMed
    1. Hanahan D, Bergers G, Bergsland E. Less is more, regularly metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105((8)):1045–1047. - PMC - PubMed
    1. Li L, Ma F. Interpretation of guidelines for the diagnosis and treatment of breast cancer during the COVID-19 outbreak. Chin J Clin Oncol. 2020;8((47))

MeSH terms